Patent ID: 7189754

Claim:
A pharmaceutical composition comprising a pyrrolidine ester according to formula (I), or a pharmaceutically acceptable salt thereof, as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein X is selected from the group consisting of CR 6 R 7 , NOR 6 , NNR 6 R 7 ; R is selected from the group consisting of C 1 –C 6 alkyl, C 2 –C 6 alkenyl, C 2 –C 6 alkynyl, aryl, C 1 –C 6 -alkyl aryl, C 1 –C 6 -alkyl-saturated 3–8-membered cycloalkyl, and C 1 –C 6 -alkyl-unsaturated 3–8-membered cycloalkyl; R 1 is selected from the group consisting of C 1 –C 6 -alkyl, aryl, saturated or unsaturated 3–8-membered cycloalkyl, acyl, and C 1 –C 6 -alkyl aryl, wherein said cycloalkyl or aryl groups may be fused with 1–2 further cycloalkyl groups or aryl groups; R 2 , R 3 , R 4 and R 5 are independently from each other selected from the group consisting of hydrogen, halogen, C 1 –C 6 -alkyl; R 6 and R 7 are independently selected from the group consisting of hydrogen, C 1 –C 6 alkyl, C 2 –C 6 alkenyl, C 2 –C 6 alkynyl, C 1 –C 6 alkoxy, C 1 –C 6 thioalkoxy, halogen, cyano, nitro, acyl, alkoxycarbonyl, aminocarbonyl, aryl, C 1 –C 6 -alkyl aryl, C 1 –C 6 -alkyl-saturated 3–8-membered cycloalkyl, and C 1 –C 6 -alkyl-unsaturated 3–8-membered cycloalkyl.